Adenoviral and baculovirus vectors are representative to a broad range of viral structures, morphologies and functions; as such they represent different engineering and manufacturing challenges. By solving key scientific and engineering questions at different scales: molecular, cellular, and bioreactor; a multi-dimensional bioengineering approach led to the development and implementation of fully integrated processes for viral vector productions. In recent years, generic knowledge and know-how has been exploited to comprehend and develop other viral vectors such as retrovirus, Adeno-Associated Viruses (AAV), lentivirus, and reovirus as well enveloped and non-enveloped Viral-Like Particles for targeted clinical applications. Very, recently, triggered by the global race for developing an alternative manufacturing solution to egg-based production of influenza vaccine, my team at NRC comprising students and post docs, discovered and carried on successful R&D pilot studies demonstrating that the Influenza viral strains are efficiently replicated in the 293 Human Embryo Kidney (HEK-293) cells and can be produced at industrial scale over timelines consistent with a massive and rapid response to a pandemic situation. (See publications on these topics)